An indirect comparison of elranatamab's (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM)
Conferences
Costa, LJ; LeBlanc, TW; Tesch, H; Sonneveld, P; Kyle, R; Sinyavskaya, L; Hlavacek, P; Meche, A; Ren, J; Schepart, A; Aydin, D; DiBonaventura, M
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 1, 2023
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
June 1, 2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Costa, L. J., LeBlanc, T. W., Tesch, H., Sonneveld, P., Kyle, R., Sinyavskaya, L., … DiBonaventura, M. (2023). An indirect comparison of elranatamab's (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).
Costa, Luciano J., Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan Kyle, Liliya Sinyavskaya, Patrick Hlavacek, et al. “An indirect comparison of elranatamab's (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Kyle R, Sinyavskaya L, et al. An indirect comparison of elranatamab's (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM). In: JOURNAL OF CLINICAL ONCOLOGY. 2023.
Costa, Luciano J., et al. “An indirect comparison of elranatamab's (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.
Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Kyle R, Sinyavskaya L, Hlavacek P, Meche A, Ren J, Schepart A, Aydin D, DiBonaventura M. An indirect comparison of elranatamab's (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM). JOURNAL OF CLINICAL ONCOLOGY. 2023.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
June 1, 2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis